Nanomedicines for the treatment of glaucoma: Current status and future perspectives

Zhai, Zimeng; Cheng, Yiyun; Hong, Jiaxu

doi:10.1016/j.actbio.2021.02.017

Cited by 18 publications

(10 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Development in ophthalmology is essential for the prevention and treatment of eye diseases, and relevant research is growing rapidly in breadth and depth and forming complex knowledge networks. Glaucoma, age-related macular degeneration, and some hereditary eye diseases were previously considered irreversible blindnesscausing diseases, and progress had been made to cure or alleviate them by modulating new targets or using new technologies (2)(3)(4). Cataracts and posterior capsular opacification were previously thought to be treated only with surgery, but in the recent years, there had been new developments in research into drugs that inhibit cataract formation (5,6).…”

Section: Introductionmentioning

confidence: 99%

Hotspots and trends in ophthalmology in recent 5 years: Bibliometric analysis in 2017–2021

et al. 2022

View full text Add to dashboard Cite

PurposeThe purpose of this study was to investigate the hotspots and research trends of ophthalmology research.MethodOphthalmology research literature published between 2017 and 2021 was obtained in the Web of Science Core Collection database. The bibliometric analysis and network visualization were performed with the VOSviewer and CiteSpace. Publication-related information, including publication volume, citation counts, countries, journals, keywords, subject categories, and publication time, was analyzed.ResultsA total of 10,469 included ophthalmology publications had been cited a total of 7,995 times during the past 5 years. The top countries and journals for the number of publications were the United States and the Ophthalmology. The top 25 global high-impact documents had been identified using the citation ranking. Keyword co-occurrence analysis showed that the hotspots in ophthalmology research were epidemiological characteristics and treatment modalities of ocular diseases, artificial intelligence and fundus imaging technology, COVID-19-related telemedicine, and screening and prevention of ocular diseases. Keyword burst analysis revealed that “neural network,” “pharmacokinetics,” “geographic atrophy,” “implementation,” “variability,” “adverse events,” “automated detection,” and “retinal images” were the research trends of research in the field of ophthalmology through 2021. The analysis of the subject categories demonstrated the close cooperation relationships that existed between different subject categories, and collaborations with non-ophthalmology-related subject categories were increasing over time in the field of ophthalmology research.ConclusionsThe hotspots in ophthalmology research were epidemiology, prevention, screening, and treatment of ocular diseases, as well as artificial intelligence and fundus imaging technology and telemedicine. Research trends in ophthalmology research were artificial intelligence, drug development, and fundus diseases. Knowledge from non-ophthalmology fields is likely to be more involved in ophthalmology research.

show abstract

Section: Introductionmentioning

confidence: 99%

Hotspots and trends in ophthalmology in recent 5 years: Bibliometric analysis in 2017–2021

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The posterior segment of eye is less accessible than the anterior segment, but it is also the region predominantly affected in degenerative diseases that lead to blindness including glaucoma, age-related macular degeneration, and diabetic retinopathy . While subconjunctival injection has shown success for delivering therapeutics, including nanoparticles to the posterior segment, , achieving similar efficacy using infrequent topical administrations for targeting this region is preferable, as it is less invasive and more convenient for patients . With these advantages in mind, soybean-based liposomes were embedded in an LDH in combination with glycylsarcosine to deliver dexamethasone to the posterior segment of the eye (Figure d) .…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

“…222 While subconjunctival injection has shown success for delivering therapeutics, including nanoparticles to the posterior segment, 223,224 achieving similar efficacy using infrequent topical administrations for targeting this region is preferable, as it is less invasive and more convenient for patients. 225 With these advantages in mind, soybean-based liposomes were embedded in an LDH in combination with glycylsarcosine to deliver dexamethasone to the posterior segment of the eye (Figure 7d). 10 Mucoadhesion is achieved via electrostatic interactions between the positively charged LDH and mucin, while glycylsarcosine promotes cellular uptake by targeting peptide transporter-1.…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Watchorn

Clasky

Prakash

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in the human body. High vascularization and accessibility have motivated drug delivery to various mucosal surfaces; however, these benefits are hindered by the mucus layer. To overcome the mucus barrier, many nanomedicines have been developed, with the goal of improving the efficacy and bioavailability of drug payloads. Two major nanoparticle-based strategies have emerged to facilitate mucosal drug delivery, namely, mucoadhesion and mucopenetration. Generally, mucoadhesive nanoparticles promote interactions with mucus for immobilization and sustained drug release, whereas mucopenetrating nanoparticles diffuse through the mucus and enhance drug uptake. The choice of strategy depends on many factors pertaining to the structural and compositional characteristics of the target mucus and mucosa. While there have been promising results in preclinical studies, mucus−nanoparticle interactions remain poorly understood, thus limiting effective clinical translation. This article reviews nanomedicines designed with mucoadhesive or mucopenetrating properties for mucosal delivery, explores the influence of site-dependent physiological variation among mucosal surfaces on efficacy, transport, and bioavailability, and discusses the techniques and models used to investigate mucus−nanoparticle interactions. The effects of non-homeostatic perturbations on protein corona formation, mucus composition, and nanoparticle performance are discussed in the context of mucosal delivery. The complexity of the mucosal barrier necessitates consideration of the interplay between nanoparticle design, tissue-specific differences in mucus structure and composition, and homeostatic or disease-related changes to the mucus barrier to develop effective nanomedicines for mucosal delivery.

show abstract

“…In response, many studies have been conducted in efforts to enhance liposome bioavailability, corneal penetration, stability, and targeted action and have achieved positive results. 69 , 70 …”

Section: Different Forms Of Ons For Cnv Therapymentioning

confidence: 99%

“…Owing to their regularly arranged framework, the unique branched topologies of dendrimers afford properties such as high solubility, availability of tremendous internal cavities loaded with various therapeutic molecules, and controllable molecular weight. 70 To date, dendrimers have been widely used as ONS for the delivery of different drugs and therapeutic agents to the eye. 104 , 105 …”

Section: Different Forms Of Ons For Cnv Therapymentioning

confidence: 99%

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

Zhang¹,

Yin²,

Zhao³

et al. 2022

IJN

View full text Add to dashboard Cite

Corneal neovascularization (CNV) is an ocular pathological change that results from an imbalance between angiogenic factors and antiangiogenic factors as a result of various ocular insults, including infection, inflammation, hypoxia, trauma, corneal degeneration, and corneal transplantation. Current clinical strategies for the treatment of CNV include pharmacological treatment and surgical intervention. Despite some degree of success, the current treatment strategies are restricted by limited efficacy, adverse effects, and a short duration of action. Recently, gene-based antiangiogenic therapy has become an emerging strategy that has attracted considerable interest. However, potential complications with the use of viral vectors, such as potential genotoxicity resulting from long-term expression and nonspecific targeting, cannot be ignored. The use of ocular nanosystems (ONS) based on nanotechnology has emerged as a great advantage in ocular disease treatment during the last two decades. The potential functions of ONS range from nanocarriers, which deliver drugs and genes to target sites in the eye, to therapeutic agents themselves. Various preclinical studies conducted to date have demonstrated promising results of the use of ONS in the treatment of CNV. In this review, we provide an overview of CNV and its current therapeutic strategies and summarize the properties and applications of various ONS related to the treatment of CNV reported to date. Our goal is to provide a comprehensive review of these considerable advances in ONS in the field of CNV therapy over the past two decades to fill the gaps in previous related reports. Finally, we discuss existing challenges and future perspectives of the use of ONS in CNV therapy, with the goal of providing a theoretical contribution to facilitate future practical growth in the area.

show abstract

Nanomedicines for the treatment of glaucoma: Current status and future perspectives

Cited by 18 publications

References 159 publications

Hotspots and trends in ophthalmology in recent 5 years: Bibliometric analysis in 2017–2021

Hotspots and trends in ophthalmology in recent 5 years: Bibliometric analysis in 2017–2021

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization

Contact Info

Product

Resources

About